The Foreign Corrupt Practices Act: Risk-Management and Compliance Strategies For Life Sciences and Pharmaceutical Companies
October 16, 2009
Just past its 30th birthday, the Foreign Corrupt Practices Act of 1977 (the FCPA or the Act) today poses the greatest liability risks ever for U.S. firms and other covered entities pursuing business opportunities abroad. Chiefly, this risk arises due to the increased risk of prosecution by the U.S. government, the government’s increased appetite for large fines, and an increased risk of multiple prosecutions due to other countries having adopted FCPA-equivalent laws.
Read the complete article by clicking on the link below.
Author(s)
Related Insights
December 5, 2025
Labor & Employment Law Perspectives
Ninth Circuit Ruling Upholds Employee Speech Amid Stalled NLRB
Like it or not, social media has become the backdrop of almost everything we do. It's how many people read the news, interact with…
December 5, 2025
Legal News: International Trade Enforcement & Compliance
What Every Multinational Should Know About … Preserving the Right to IEEPA Tariff Refunds
Any company that has imported goods subject to the Trump administration’s fentanyl-based tariffs or reciprocal tariffs — i.e., the tariffs levied pursuant to the International Emergency Economic Powers Act (the IEEPA tariffs) — needs to consider filing an action in the U.S. Court of International Trade (CIT) to preserve the possibility of recovering refunds of these tariffs.
December 4, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…